In an investigation of the effect of rifampin on the immune response in mice, the cellular immunity was evaluated with the split-heart allograft technique. The survival time of the heart in animals treated with rifampin at a dose of 20 mg/kg per day from the day of the transplantation until the graft was rejected was longer (33.7 days, P < 0.001) than that of animals not treated with antibiotics (14.5 days). When rifampin was given at a dose of 5 mg/kg per day for the same period, the mean survival time of allografts was 19.5 days. The number of demonstrable plaques of hemolysis and the humoral antibodies to sheep erythrocytes were also reduced by a human therapeutic dose (20 mg/kg per day). However, the suppression of the humoral immune response was probably of more limited biological significance, suggesting a differential sensitivity to rifampin. In contrast to rifampin, benzylpenicillin had no noteworthy inhibiting effect on the cellular or humoral immune response.
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Rifampin, an antibiotic that inhibits bacterial deoxyribonucleic acid dependent ribonucleic acid polymerase and is readily soluble in lipids (10, 16) , has previously been controversially described as an immunosuppressive agent (1, 3, 9, 21) . Recent in vitro studies in our laboratory have demonstrated that this antibiotic markedly inhibits the chemotaxis of human polymorphonuclear leucocytes as well as the lymphoproliferative response of the human lymphocytes stimulated with mitogens (7, 8) .
The purpose of the present study was to elucidate the effect of rifampin on both the humoral and the cellular immune response in mice. Rejection of tissues or organs transplanted in allogenic recipients has been generally regarded as an example of cellular immunity, implying that it is probably lymphocytes arising in the thymus that are mainly responsible for initiating such rejection. In the investigation of cellular immunity, the split-heart allograft technique has been used (23 Transplantation. Heart grafts were transplanted with a modification of the Judd and Trentin method (13, 23) . Hearts from newborn DBA mice were sectioned along the ventricular septum and each half was inserted into a subcutaneous pouch in the dorsal part of the ear of the recipient CBA mouse. The survival of the transplant was monitored by measuring the electric activity with a Mingograf 61 with an integrated amplifier. The activity of the host hearts was also recorded. This activity differed from that of the transplanted hearts and did not confuse measurements.
Statistics. Statistically evaluated tests were performed to determine whether the results obtained might be significant. Student's t test was used.
RESULTS
Toxicity of rifampin. Rifampin was apparently well tolerated by the mice when given in an HTD or 1/4 HTD. However, when rifampin was given in a larger dose (5 HTD), signs of toxicity appeared, such as loss of body weight.
Determination of rifampin serum level. The serum concentration of rifampin was determined microbiologically 2 h after injection. In mice given 5 mg of rifampin per kg per day (1/4 HTD), the serum concentration of the antibiotic ranged from 6 to 13 ,ug/ml, and in mice given 20 mg/kg per day (HTD), it ranged from 17 to 28 Ag/ml. 27 14 10 16 100 a ,50 -
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Survival time of allografts. As reference, untreated transplanted mice were used. Figure   1 illustrates the effect of rifampin given i.p. on the survival time of split-heart allografts from DBA mice in CBA mice. Daily antibiotic treatment was given from the day of transplantation until rejection of the grafts was detected with an electrocardiograph. A remarkable and significant (P < 0.001) delay occurred in the rejection of the grafts in the mice given rifampin in an HTD (20 mg/kg per day) (Fig. 1) . The mean survival time ± standard deviation (MST ± SD) was 33.7 ± 9.6 days, compared with 14.5 ± 3 days in the reference group. When rifampin was given in a dose of 5 mg/kg per day (1/4 HTD) for the same period, an MST ± SD of 19.5 ± 4.1 days was detected, which also differed significantly from the reference group (P < 0.01). Figure 1 also illustrates that penicillin given i.p. for the same period did not prolong the survival of the grafts (15.9 ± 3.9 days).
A marked prolongation (P < 0.001) of survival of allografts was also noted in mice given rifampin at an HTD from 20 days and 10 weeks before transplantation and every day until rejection (Fig. 2) . The MST was 25.2 ± 6.2 days and 24.2 ± 5.7 days, respectively. Figure 2 also shows that in mice treated only from the day of transplantation, the rejection was later (33.7 days) than in the pretreated groups, but the difference was not significant (P > 0.4). Figure 3 illustrates the effect of an HTD of rifampin on the survival time of allografts when given daily from the day of transplantation until day 7 or from day 9 after transplantation until rejection. In both groups survival was significantly prolonged (P < 0.01). However, the effect Percentage of surviving split-heart allografts in CBA mice treated daily with an HTD of rifampin from the day of the transplantation until the rejection of the grafts (U), from the day of transplantation until day 7 after transplantation (E), or from day 9 after transplantation until rejection of the grafts (0). Untreated transplanted mice (0) served as a reference. Numbers at top of each curve denote the number of transplantation experiments in each group. of the drug was less pronounced (P < 0.02) in these groups of mice than in the group given rifampin from the day of the transplantation until the rejection of the allografts (Fig. 3) .
Antibody-producing cells. The direct plaque-forming cells from spleens of mice immunized with SRBC and treated with rifampin or penicillin from the day of immunization with or without pretreatment, were analyzed. When the mice were treated with rifampin in a dose of 20 mg/kg per day from the day of immunization until day 3, only 52% + 5% of the number of plaques of hemolysis obtained with the spleens of untreated immunized mice was detected (P < 0.001) (Fig. 4) . The (19, 20) and Nilsson (17) .
The present study shows that rifampin significantly delays rejection when given daily in an HTD (20 mg/kg per day) from the day of the transplantation. The immunosuppressive effect appeared weaker when treatment with rifampin was started before the transplantation, presumably because the mice became accustomed to the antibiotic, probably owing to the induction of deacetylating liver enzymes (18) . Treatment performed only before the transplantation or discontinued on day 7 after transplantation inhibited the immune response less, which contrasts with the usual lympholytic immunosuppressants, such as corticosteroids (2) . Treatment started day 9 after transplantation also notably delayed the rejection of the allografts, an effect which might prove clinically useful in the prevention of graft rejection. Serrou et al. (21) The mechanism of interaction of rifampin with the responding cells is obscure. There is general consensus that macrophages are present in an allograft bed and are necessary for the primary antibody response to T-cell-dependent antigen (15) . One might therefore imagine that the immunosuppressive effect demonstrated is related to an inhibition of the phagocytic activity (1) . However, the immunosuppressive properties of rifampin can be ascribed to its ability to diffuse into human cells, owing to its ready liposolubility and to its inhibition of protein synthesis in lymphocytes. The availability of an antibiotic with immunosuppressive additive effect when used in combination with immunosuppressants can be useful in clinical situations for treatment of patients with inflammatory diseases and for transplanted patients. However, the immunosuppressive properties of rifampin may also be an important adverse effect of the drug.
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